 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
13 News |  |
- ||| LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion, Combination therapy: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Mar 28, 2022
P1, N=298, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- || LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Oct 25, 2021
P1, N=298, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Aug 2022 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
- || LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Jul 2, 2021
P1, N=298, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2022 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Dec 2021 Recruiting --> Active, not recruiting
- | LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Combination therapy: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - May 5, 2021
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Sep 2021 --> Aug 2022
- || LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Apr 21, 2020
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2021 --> Aug 2022 Trial completion date: Feb 2021 --> May 2021 | Trial primary completion date: Feb 2021 --> May 2021
- || LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Jan 22, 2020
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2021 --> May 2021 | Trial primary completion date: Feb 2021 --> May 2021 Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Nov 2019 --> Feb 2021
- || LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Jun 18, 2018
P1, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Nov 2019 --> Feb 2021 Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Nov 2019
- ||| LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Feb 6, 2017
P1, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Nov 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2018 --> May 2019
- ||| LCL161 / Novartis, spartalizumab (PDR001) / Novartis
New P1 trial, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Sep 7, 2016
P1, N=350, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- QBM076 / Novartis
Trial primary completion date: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Mar 24, 2016
P2, N=48, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2018 --> May 2019 Trial primary completion date: Dec 2015 --> May 2015
- QBM076 / Novartis
Enrollment change, Trial termination: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Sep 30, 2015
P2, N=48, Terminated, Sponsor: Novartis Pharmaceuticals
N=122 --> 48 | Recruiting --> Terminated; Part 1 was completed. Part 2 was terminated for safety reasons.
- || QBM076 / Novartis
Trial primary completion date: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Apr 21, 2014
P2, N=122, Recruiting, Sponsor: Novartis Pharmaceuticals
Part 2 was terminated for safety reasons. Trial primary completion date: Jul 2015 --> Oct 2015
- || QBM076 / Novartis
Trial completion date: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Apr 21, 2014
P2, N=122, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2015 --> Oct 2015 Trial completion date: Jul 2015 --> Oct 2015
- |||| QBM076 / Novartis
Enrollment open: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Dec 8, 2013
P2, N=122, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- ||||| QBM076 / Novartis
New P2 trial: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. (clinicaltrials.gov) - Oct 28, 2013
P2, N=122, Recruiting, Sponsor: Novartis Pharmaceuticals